Keyonote lecture – Francesco Pignatti (EMA, NL)

Navigating the evolving regulatory landscape of orphan drugs in Europe – Pedro Franco (Merck Healthcare KGaA, UK)

The EU Clinical Trial Information System public portal – Francesca Scotti (EMA, NL)

Rare cancers: challenges for new treatment developments in the precision medicine era – Jean-Yves Blay (Centre Léon Bérard; UNICANCER, FR)

EORTC TRACE platform – Denis Lacombe (EORTC, BE)

Precision oncology: a revolution for rare cancers – David Thomas (OMICO, AU) – did not consent

Accelerating drug development through Fostering Age Inclusive Research (ACCELERATE- FAIR) – Nathalie Gaspar (Gustave Roussy , FR)

EU HTA – HTA perspective – Beate Wieseler (Institute for Quality and Efficiency in Health Care (IQWiG), DE)

Testimony on the path for access (patient perspective) – Max Williamson (Beatson West of Scotland Cancer Centre, UK)

Testimony on the path for access (medical professional perspective) – Winette Van der Graaf (EORTC, NL)

Regulatory perspective (FDA) – Timil Patel (FDA, US)

Opportunities and Challenges of Managing Early Access in Rare Cancers: An Industry Perspective – Philipp Schlatter (Roche, CH)

Patient access & data collection/ownership – Rachel Giles (VHL Europa, NL)

DRUP – across countries studies – Sahar Van Waalwijk van Doorn-Khosrovani (CZ Health Insurance, NL) – did not consent